Abstract

Purpose: To create a set of benchmark data, using the AAPM TG1 19 test suite, for 6MV flattening‐filter free IMRT/VMAT plans to compare with 6MV IMRT/VMAT plans and with TG119 multi‐institutional results. Methods: TG1 19 test cases were created: AP/PA, multiple dose bands, and 5 patient cases (c‐shape tumor with easy and hard dosimetric constraints, headn low dose: −0.4% +/− 1.0%). There was no significant difference between IMRT and VMAT results (p=0.9696). However, results were significantly different (p=0.0003) for 6MV (−0.3% +/− 1.0%) and 6MVFFF (−1.1% +/− 1.2%). This could be due to beam modeling differences from commissioning, to increased dose gradients in the 6MVFFF beam which may increase the measurement uncertainty, or to other measurement issues (Pion variability). There was no statistically significant difference between the results in the high and low dose regions (p=>0.1000). Prostate and H&N plans all measured lower than planned while the C‐shape and Multi‐target plans didn't show any consistent higher/lower trends compared to planned doses. Conclusions: While 6MVFFF and 6MV results were acceptable, there is room for improvement of the 6MVFFF accuracy. In future work we will investigate the effects of changing the 6MVFFF beam model and increasing the accuracy of the ion chamber measurements. Additionally, we will extend our analysis to 2D (film) and 3D (radiochromic dosimeter PRESAGE(TM).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.